Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Mod Pathol

Retrieve available abstracts of 14 articles:
HTML format

Single Articles

    November 2022
  1. YU Y, Lajkosz K, Finelli A, Fleshner N, et al
    Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification.
    Mod Pathol. 2022;35:1695-1701.
    PubMed     Abstract available

    August 2022
  2. CHAN E, McKenney JK, Hawley S, Corrigan D, et al
    Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.
    Mod Pathol. 2022;35:1092-1100.
    PubMed     Abstract available

    May 2022
  3. SHAH RB, Palsgrove DN, Desai NB, Gagan J, et al
    Enrichment of "Cribriform" morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer.
    Mod Pathol. 2022 May 23. pii: 10.1038/s41379-022-01093.
    PubMed     Abstract available

    April 2022
  4. JUNG M, Jin MS, Kim C, Lee C, et al
    Artificial intelligence system shows performance at the level of uropathologists for the detection and grading of prostate cancer in core needle biopsy: an independent external validation study.
    Mod Pathol. 2022 Apr 29. pii: 10.1038/s41379-022-01077.
    PubMed     Abstract available

  5. CAHILL LC, Rosen S, Yoshitake T, Wu Y, et al
    Real-time diagnosis and Gleason grading of prostate core needle biopsies using nonlinear microscopy.
    Mod Pathol. 2022;35:539-548.
    PubMed     Abstract available

    December 2021
  6. SCHOMIG-MARKIEFKA B, Pryalukhin A, Hulla W, Bychkov A, et al
    Quality control stress test for deep learning-based diagnostic model in digital pathology.
    Mod Pathol. 2021;34:2098-2108.
    PubMed     Abstract available

    November 2021
  7. PAN CC, Epstein JI
    Reexamining the molecular findings in specialized stromal tumors of the prostate.
    Mod Pathol. 2021;34:2080-2081.

  8. ACOSTA AM, Sholl LM, Marino-Enriquez A, Dal Cin P, et al
    In Response to "Reexamining the molecular findings in specialized stromal tumors of the prostate".
    Mod Pathol. 2021;34:2082-2083.

    September 2021
  9. FERGUSON DC, Mata DA, Tay TK, Traina TA, et al
    Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations.
    Mod Pathol. 2021 Sep 30. pii: 10.1038/s41379-021-00924.
    PubMed     Abstract available

  10. CHATRIAN A, Colling RT, Browning L, Alham NK, et al
    Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies.
    Mod Pathol. 2021;34:1780-1794.
    PubMed     Abstract available

  11. ACOSTA AM, Sholl LM, Dickson BC, McKenney JK, et al
    Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.
    Mod Pathol. 2021;34:1763-1779.
    PubMed     Abstract available

    June 2021
  12. HANSUM T, Hollemans E, Verhoef EI, Bangma CH, et al
    Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.
    Mod Pathol. 2021 Jun 26. pii: 10.1038/s41379-021-00860.
    PubMed     Abstract available

    March 2021
  13. BULTEN W, Balkenhol M, Belinga JA, Brilhante A, et al
    Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists.
    Mod Pathol. 2021;34:660-671.
    PubMed     Abstract available

    April 2020
  14. ZHU MMT, Burugu S, Gao D, Yu J, et al
    Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
    Mod Pathol. 2020 Apr 29. pii: 10.1038/s41379-020-0550.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.